Equity in Access to GU Clinical Trials: What Are the Factors That May Impact Toxicity and Efficacy? Are We Lacking Diversity in IO Trials? How Can We Solve Most Common Barriers?

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

10 seconds

Equity in Access to GU Clinical Trials: What Are the Factors That May Impact Toxicity and Efficacy? Are We Lacking Diversity in IO Trials? How Can We Solve Most Common Barriers?

By Virtual Diversity in Cancer Care FEATURING Tanya Barauskas Dorff

5 views

December 7, 2020

0 Comments

Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…

Feat. S. Ratnam

The Man Cave

Feat. J. Hamilton, M. Fabrizio, M. Taha

Cancer Screening in Primary Care: An Evidence-Based Review of Outpat…

Feat. N. Robertson

25:23

Houston Methodist Hospital

Whole-Body MRI: Past, Present, and Future

Feat. N. Gupta

13:37

SIR 2023 Conference Coverage

SIR 2023: Renal Cell Carcinoma Guidelines - What's New in 2023?

Feat. N. Kothary

19:22

Janssen Oncology

Doc Talk Podcast

Feat. J. Hamilton, M. Fabrizio, M. Taha

19:47

Janssen Oncology

All Things PSA

Feat. J. Hamilton, M. Fabrizio, M. Taha

51:15

Masonic Cancer Center, University of Minnesota

Cooked Meat and Prostate Cancer

Feat. R. Turesky

04:13

Karine Tawagi

Diagnostic and Therapeutic Updates in mCRPC: Radioligand Therapy

49:46

Masonic Cancer Center, University of Minnesota

Biomarkers and Biology: Treatment Resistance in Advanced Prostate Ca…

Feat. J. Lang

08:03

UCLA Health

Managing Advanced Prostate Cancer Pts in Urology Clinics and When to…

Feat. I. Garraway

12:19

UNC Lineberger Comprehensive Cancer Center

UNC Prostate Cancer Screening Updates

Feat. H. Tan

13:22

OncoAlert

Urology Year in Review: Prostate Cancer Screening, EMBARK Trial, PSM…

Feat. A. Merseburger

09:53

Insights from 2024 ASCO® GU Annual Meeting

Real-World Genomic Testing Patterns in Patients With Prostate Cancer

Feat. D. Kaakour

30:29

Icahn School of Medicine at Mount Sinai

Mount Sinai School of Medicine Prostate Cancer Updates

Feat. C. Tsao

03:19

Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "Difference in High-Risk Prostate Cance…

Feat. S. Semko

07:53

Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "Transperineal Versus Transrectal Prost…

Feat. J. Hu

05:18

ASCO GU 2023 Conference Coverage

ASCO GU 2023: Dr. Miron and Dr. Park Discuss Kidney and Bladder Upda…

Feat. B. Miron, C. Park

21:57

International Urology Cancer Summit - IUCS

Today Biomarkers and Targets in GU Cancers

Feat. P. Rescigno

10:56

Insights from 2024 ASCO® GU Annual Meeting

ASCO® GU 2024 Insights: "From CHAARTED Low- and High-Volume Dis…

Feat. L. Unterrainer

19:38

PROSCA & BLADDR 2023

Prostate Cancer Screening and Organized Testing

Feat. A. Rannikko

14:25

GRACE

The Role of ctDNA Biomarker in Bladder Cancer

Feat. J. Brown

Login

Login

Join VuMedi

Equity in Access to GU Clinical Trials: What Are the Factors That May Impact Toxicity and Efficacy? Are We Lacking Diversity in IO Trials? How Can We Solve Most Common Barriers?

Related Content